Using a graphical risk tool to examine willingness to take migraine prophylactic medications

Abstract: Many migraine sufferers use daily prophylactic therapy to reduce the frequency of their headache attacks. The Food and Drug Administration has approved several different medications for migraine prophylaxis, but it is not clear whether sufferers perceive these treatments to provide clinically significant benefits given their side effect profiles. Three hundred headache sufferers were recruited from the community and local headache clinics using print and television advertising. Participants reported experiencing problematic headache attacks with a median (IQR) frequency of 7.0 (4-13) headache days per month. These sufferers participated in a cross-sectional, single-site, study that used a specially designed computer assessment task. Participants were instructed on the probability of experiencing the 3 most commonly experienced side effects for several blinded medication profiles: divalproex sodium, venlafaxine, gabapentin, propranolol, and topiramate. After learning the likelihood of experiencing side effect profiles of each medication, participants were asked whether they would be willing to take the medication for a given headache reduction level, which ranged from 0 to 7 days per month. The side effect profile for divalproex sodium was associated with the smallest willingness to take, with gabapentin, propranolol, and topiramate perceived to be much more agreeable. However,
Source: Pain - Category: Anesthesiology Tags: Research Paper Source Type: research

Related Links:

TUESDAY, Nov. 19, 2019 -- Acute treatment of migraine with ubrogepant leads to significantly greater rates of pain freedom at two hours than placebo, according to a study published online Nov. 19 in the Journal of the American Medical...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
(CNN) — A new drug to treat migraines has shown promise in a large-scale clinical trial, offering hope to people unable to use current treatment options. The drug, ubrogepant, showed greater rates of pain and symptom relief from migraine compared to a placebo, with more than 20% of participants given the drug reporting to be pain-free within two hours and more than 34% relieved of the most bothersome symptoms linked to migraine, which include light and noise sensitivity. This is compared to 14% and 27%, respectively, from the placebo. “Having ubrogepant as a potential new medication for the acute treatment of m...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News CNN Migraines Source Type: news
Migraine sufferers might soon have a new weapon against the pain, nausea and light sensitivity that come with the headaches. A new drug by Allergan, ubrogepant, shows promise in trial results released Tuesday.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news
We report a case of rhabdomyolysis following epidural steroid injection for lumbar radiculopathy. PMID: 31736023 [PubMed - in process]
Source: Agri Dergisi - Category: Anesthesiology Tags: Agri Source Type: research
Authors: Çimen Atalar A, Yalın OÖ, Aslan H, Baykan B Abstract OBJECTIVES: There are only a handful of studies examining the clinical differences between patients with and without a family history of migraine. Our aim is to compare the descriptive and clinical properties of patients with and without a family history, and to investigate the association between the migraine burden and disease characteristics and disability of migraine. METHODS: A total of 530 consecutive patients diagnosed with migraine according to the International Headache Society criteria were enrolled into the study. Detailed sys...
Source: Agri Dergisi - Category: Anesthesiology Tags: Agri Source Type: research
Migraine headache is an episodic phenomenon, and patients with episodic migraine have ictal (headache), peri-ictal (premonitory, aura, and postdrome), and interictal (asymptomatic) phases. We aimed to find the functional characteristics of the migraine brain regardless of headache phase using dynamic functional connectivity analysis. We prospectively recruited 50 patients with migraine and 50 age- and sex-matched controls. All subjects underwent a resting-state functional magnetic resonance imaging. Significant networks were defined in a data-driven fashion from the interictal (>48 hours apart from headache phases) pati...
Source: Pain - Category: Anesthesiology Tags: Research Paper Source Type: research
PMID: 31739342 [PubMed - in process]
Source: Annals of Internal Medicine - Category: Internal Medicine Authors: Tags: Ann Intern Med Source Type: research
PMID: 31739341 [PubMed - in process]
Source: Annals of Internal Medicine - Category: Internal Medicine Authors: Tags: Ann Intern Med Source Type: research
Condition:   Episodic Migraine Interventions:   Device: Sham Treatment Location;   Device: Verum Treatment Location Sponsor:   Theranova, L.L.C. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractPurpose of ReviewThe purpose of this review is to summarise the current state of knowledge concerning known types of gain, the reasons why patients might seek it, as well as implications for headache disorders.Recent FindingsEven though the subject has been studied in the past, it received less attention in recent years.SummaryThere is no doubt that migraine is a highly disabling disorder. However, attacks sometimes may be beneficial for the migraine brain as a time-out from the daily routine. On the other hand, patients are often stigmatised as trying to satisfy other needs through their disease. These “othe...
Source: Current Pain and Headache Reports - Category: Neurology Source Type: research
More News: Advertising | Computers | Divalproex Sodium | Effexor | Food and Drug Administration (FDA) | Gabapentin | Headache | Inderal | Learning | Migraine | Neurontin | Pain | Study | Topamax | Universities & Medical Training